People Bereaved by Violent Death : Negative Event Biases and Temporal Perception
PrEVENT
1 other identifier
interventional
61
1 country
1
Brief Summary
A violent death is defined by its brutality, unexpectedness and is secondary to an external cause (suicide, homicide, accident). Bereavement following a violent death constitutes a particular clinical situation, at risk of complications. Research on bereavement after a violent death shows higher risks of psychiatric and somatic complications than in bereavement by non-violent death. These complications, sometimes comorbid, take the form of depressive episodes, post-traumatic stress disorders, suicidal behavior and prolonged grief disorders after 12 months, precociously mediated by ruminations. Processes responsible for this increased risk of complications are poorly documented. Current literature relates mainly to socio-demographic and epidemiological factors which, alone, do not explain this difference in risks. Further research is needed exploring other kinds of data and processes. To our knowledge, there is no description of early neurocognitive functioning in people bereaved after violent death. This study aims at exploring early neurocognitive processes which can lead to complications in people bereaved by violent death.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2023
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 12, 2023
CompletedFirst Posted
Study publicly available on registry
May 24, 2023
CompletedStudy Start
First participant enrolled
September 19, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
ExpectedMarch 6, 2025
March 1, 2025
2.4 years
May 12, 2023
March 4, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Amplitude of the Late Positive Potential (LPP) component in unpredictable event condition
Measure in Electroencephalography (EEG) of the Late Positive Potential (LPP), an Event Related Potential (ERP) relating to attention biases
Between Day15 and Day30 after the death of one's loved one
Secondary Outcomes (3)
Amplitude of the Contingent Negative Variation (CNV ) component in unpredictable event condition
Between Day15 and Day30 after the death of one's loved one
Amplitude of the alpha and beta power in unpredictable event condition
Between Day15 and Day30 after the death of one's loved one
Comparison of Constant Errors (CE) relative to time estimates in the unpredictability condition (D15-J30) in people developing a psychiatric complication at 3 months and in people not developing these complications.
Between Day15 and Day30 after the death of one's loved one
Study Arms (2)
Group with complications at 3 month
OTHERGroup composed with participants who develop a psychiatric complication (depressive episode or post traumatic stress disorder) 3 month after the death of their loved one.
Group without complication at 3 month
OTHERGroup composed with participants who do not develop a psychiatric complication (depressive episode or post traumatic stress disorder) 3 month after the death of their loved one.
Interventions
Clinical diagnosis of depressive episode or post traumatic stress disorder, confirmed
No elements in clinical assessment for the diagnosis of a depressive episode or post traumatic stress disorder
Eligibility Criteria
You may qualify if:
- An age between 18 and 65 years old
- Recent bereavement by violent death of a relative in first and second degree
You may not qualify if:
- Protected adults
- Lack of mastering French language
- History of neurodegenerative disorder
- History of psychiatric disorder treated pharmacologically with modification of the basic treatment in the month preceding the death
- The take of an benzodiazepine treatment in the 24th hours before the first visit (T0)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hopital Vinatier
Bron, 69678, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Edouard LEAUNE
Vinatier Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- SCREENING
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 12, 2023
First Posted
May 24, 2023
Study Start
September 19, 2023
Primary Completion
February 28, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
March 6, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share